<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727181</url>
  </required_header>
  <id_info>
    <org_study_id>CS05002TV</org_study_id>
    <nct_id>NCT00727181</nct_id>
  </id_info>
  <brief_title>An Observational, Prospective Evaluation of the Trifecta™ Valve</brief_title>
  <official_title>An Observational, Prospective Evaluation of the Trifecta™ Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to confirm the clinical safety and effectiveness of the Trifecta valve&#xD;
      by establishing associated adverse event rates, clinical status as indicated by New York&#xD;
      Heart Association (NYHA) functional classification, hemodynamic performance, and hematology&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical investigation is a multi-center, multi-country, prospective, non-randomized,&#xD;
      observational study without concurrent or matched controls, designed to evaluate the safety&#xD;
      and effectiveness of the Trifecta valve. A maximum of 120 subjects requiring aortic valve&#xD;
      replacement will be implanted at a maximum of 6 investigational sites in Europe. The sample&#xD;
      size is based on late patient-years of follow-up with a minimum of 400 late patient-years&#xD;
      experience required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize patient NYHA functional classification status</measure>
    <time_frame>CE labelling</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the hemodynamic performance of the valve, as per echocardiography</measure>
    <time_frame>CE labelling</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>CE labelling</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Regurgitation, Aortic Valve</condition>
  <condition>Aortic Valve Incompetence</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Trifecta Valve</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trifecta aortic heart valve</intervention_name>
    <description>Replacement of a diseased, damaged, or malfunctioning aortic heart valve</description>
    <arm_group_label>Trifecta Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient requires aortic valve replacement. (Note: patients undergoing concomitant&#xD;
             procedures, e.g. coronary artery bypass grafting, or valve repair, are eligible for&#xD;
             this study).&#xD;
&#xD;
          2. Patient is legal age in host country.&#xD;
&#xD;
          3. Patient (or legal guardian) has given written informed consent for participation prior&#xD;
             to surgery.&#xD;
&#xD;
          4. Patient is willing to undergo all study procedures and adhere to data collection and&#xD;
             follow-up requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is pregnant or nursing (women of child bearing potential must have a&#xD;
             documented negative pregnancy test within one week prior to surgery).&#xD;
&#xD;
          2. Patient already has a prosthetic valve(s) at a site other than the aortic valve.&#xD;
&#xD;
          3. Patient requires concomitant replacement of the tricuspid, pulmonary, or mitral valve.&#xD;
&#xD;
          4. Patient has an inability or is unwilling to return for the required follow-up visits.&#xD;
&#xD;
          5. Patient has active endocarditis (patients with previous endocarditis must have two&#xD;
             documented negative blood culture results prior to enrollment).&#xD;
&#xD;
          6. Patient has had an acute preoperative neurological event defined as patient has not&#xD;
             returned to baseline or has not stabilized 30 days prior to the planned valve&#xD;
             implantation surgery.&#xD;
&#xD;
          7. Patient is undergoing renal dialysis.&#xD;
&#xD;
          8. Patient has a documented history of substance abuse within one year of enrollment or&#xD;
             is currently a prison inmate.&#xD;
&#xD;
          9. Patient is currently participating in the study of an investigational drug or device,&#xD;
             or the patient was previously participating in an investigational drug study and has&#xD;
             not completed a 30-day wash out period.&#xD;
&#xD;
         10. Patient had the Trifecta valve implanted as part of this study, but then had the&#xD;
             device explanted.&#xD;
&#xD;
         11. Preoperative evaluation indicates other significant cardiovascular abnormalities such&#xD;
             as aortic dissection or ventricular aneurysm.&#xD;
&#xD;
         12. Patient has a life expectancy less than two years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich W Mohr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitat Herzzentrum Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 29, 2008</study_first_submitted>
  <study_first_submitted_qc>July 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic valve</keyword>
  <keyword>heart valve</keyword>
  <keyword>tissue valve</keyword>
  <keyword>bioprosthesis</keyword>
  <keyword>valve disorder</keyword>
  <keyword>valve disease</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>aortic valve regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

